Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty.
BACKGROUND
The relationships among the circulating levels of endothelial progenitor cells (EPC), stromal cell-derived factor (SDF)-1alpha, interleukin (IL)-10 and outcome were examined in patients with ST-segment elevation acute myocardial infarction (ST-se AMI) undergoing primary coronary angioplasty.


RESULTS
Circulating levels of IL-10, SDF-1alpha, and EPCs [defined by staining markers: CD31/CD34 (E(1)) and KDR/CD34 (E(2))] were examined by ELISA and flow cytometry, respectively. The IL-10 level was higher, whereas the circulating level of EPCs (E(1-2)) was lower (all P<0.05) in AMI patients than in normal subjects. Additionally, the SDF-1alpha level was significantly and independently predictive of an increased level of circulating EPCs (E(1-2)) (P<0.0001). Furthermore, patients with a high SDF-1alpha level (>1,500 pg/ml) had lower left ventricular performance, higher Killip score (defined as >or=3), and increased 30-day mortality than those with low SDF-1alpha level (<or=1,500 pg/ml) (all P<0.007). Moreover, high circulating levels of E(2) and IL-10 were the most significant independent predictors of increased 30-day major adverse clinical outcome (MACO) (defined as advanced Killip score >or=3 or 30-day mortality) (P<0.01).


CONCLUSIONS
The serum SDF-1alpha level is independently predictive of an increased level of circulating EPCs (E(1-2)). E(2) and IL-10 are major independent predictors of 30-day MACO in ST-se AMI patients undergoing primary coronary angioplasty.
Chang
Li-Teh
LT
Basic Science, Nursing Department, Meiho Institute of Technology, Pingtung, Taiwan, ROC.
Yuen
Chun-Man
CM
Sun
Cheuk-Kwan
CK
Wu
Chiung-Jen
CJ
Sheu
Jiunn-Jye
JJ
Chua
Sarah
S
Yeh
Kuo-Ho
KH
Yang
Cheng-Hsu
CH
Youssef
Ali A
AA
Yip
Hon-Kan
HK
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D018952:Antigens, CD34 / Q000097:blood*; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000097:blood*; D004730:Endothelium, Vascular / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D059630:Mesenchymal Stem Cells / Q000276:immunology / Q000473:pathology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000097:blood; D011237:Predictive Value of Tests; D011379:Prognosis; D012044:Regression Analysis; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood
D018952:Antigens, CD34; D054377:Chemokine CXCL12; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D016753:Interleukin-10; D040301:Vascular Endothelial Growth Factor Receptor-2